During our next X-Novation Talks on Biotech, we discussed the topic of personalized medicine thanks to data with Julie Baussand, health innovation project manager at Medicen, the competitiveness cluster for innovative health technologies in Ile de France.
The importance of data for personalized medicine
First of all, what is personalized medicine? This approach to medicine consists of adapting treatments according to the characteristics of patients and their diseases. The goal is to provide patients with highly accurate diagnoses and personalized care.
Personalized medicine is made possible by the analysis of health data, in particular thanks to Big Data. Health data allows us to better predict patient responses to different treatment options and to avoid side effects as much as possible.
We also talk about 4P medicine," adds Julie Baussand. Personalized, predictive, preventive and participatory. Personalized because it is based on the patient's specific data, Predictive because it makes it possible to assess the risk of developing diseases or responding to a treatment, Preventive because it promotes actions to preserve the patient's health and finally Participatory because by sharing their data, the patient becomes an actor in their health.
Thanks to personalized medicine, healthcare professionals are offering patients an optimized care pathway. Data comes from computerized patient records, connected objects, health applications, etc. Their strength lies in gathering this data and analyzing it, particularly with artificial intelligence software.
The ambition of 4P medicine is to profoundly transform the healthcare system by basing it more on personalized prevention rather than on a collective curative approach.
The influence of data on current medicine
To date, digital health that fosters the development of 4P medicine is in its infancy, but Covid-19 has accelerated the adoption of digital solutions and the sharing of health data, resulting in particular in the deployment of the Health Data Hub that was launched earlier than expected during the crisis, explains Julie Baussand.
Data is perceived as a real goldmine in the healthcare field and there is a real desire to exploit it to improve patient care. Numerous initiatives are emerging, particularly within university hospitals, to provide access to this data in order to promote innovation in healthcare while preserving patient safety.
To help the ecosystem on the road to sharing health data, Medicen has set up a roadmap dedicated to the challenges of health data and related digital solutions. In particular, "Meet My Data", a monthly meeting whose objective is to decipher the existing health data panorama, identify the players and thus encourage collaborative projects around health data.
Nevertheless, the acceleration of the exploitation of data and digital health solutions depends on several necessary aspects to be addressed in their entirety. For example, regulated and secure access to health data, the use of reliable and explainable artificial intelligence, system interoperability, data quality and standardization, etc.
France is evolving on these subjects and is organizing itself to provide solutions and structure the ecosystem, notably at the European level with initiatives such as TEDHaS or GAIA-X. Abroad, the digital transformation of the healthcare system and the use of health data is underway, for example in Germany with the DiGA (Digital Health Applications), which by allowing the reimbursement of digital solutions will accelerate their adoption, the development of start-ups and the generation of health data.
The will to move forward is very much present in France," says Julie Baussand. There is a strong national will from politicians and the ecosystem. Medicen is organizing a virtual event on the use of real-life data in decision-making on June 11, 2021. It's a morning of restitution of the work done in the framework of the AI and Health program of the CSF Health Industries and Technology and led by ARIIS.
Data protection: the challenge of personalized medicine
Among the keys to promoting the development of health data analysis in France, the protection of patients and their data is a major issue.
One example is the controversy surrounding the choice of Microsoft to host the Health Data Hub platform, because of the Cloud Act, which under certain conditions allows American authorities to access data hosted by American companies, regardless of their location. In response, the hosting provider is expected to change within 2 years if a better technical solution is proposed.
From my perspective, patients are quite willing to share this data for research and innovation purposes, but only if they have confidence that the data will be secure and used appropriately. Trust is the key to structuring this ecosystem and moving forward. This is Medicen's objective, explains Julie Baussand
The role of Medicen
Medicen is the healthcare competitiveness cluster of the Ile de France region. It was created in 2005 and aims to bring together the private and public healthcare ecosystem to develop innovative solutions for patients.
Medicen is organized into three sectors: Biotech, MedTech and E-health, with cross-cutting issues such as health data. The cluster has 3 levers of action to support the health and innovation sector
- Supporting players in the ecosystem (over 500 members) in the emergence and development of innovation projects;
- Guiding project leaders towards dilutive and non-dilutive financing mechanisms;
- Supporting the development of companies in Europe and internationally.
X-Novation Talks : Biotech et innovations
Want to learn more about personalized medicine? Don't miss the next X-Novation Talks on the topic of Biotech and related innovations. The invited experts will address the subject of health data, artificial intelligence software and globally the medicine of the future.
In addition to Julie Baussand, head of health innovation projects at Medicen, you will have the pleasure of discussing with Stéphane Bidet, CEO of Hillo, Louis-Oscar Morel, CEO of Ummon HealthTech and Marc Lavielle, director of research in statistics at INRIA and professor at the Applied Mathematics Center of the École Polytechnique.